Australia Primary Hyperoxaluria (PH) Market
Primary Hyperoxaluria (PH) is a rare inherited (genetic) condition present at birth. In PH, oxalates are overproduced. Excess oxalate is eliminated through the kidneys, in urine. The extra oxalate combines with calcium to create kidney stones and crystals, which damage the kidneys and cause renal failure. Primary hyperoxaluria is estimated to affect 1 in 58,000 individuals worldwide. While for Australia it affects 1 in 419,068. Australian Primary Hyperoxaluria (PH) therapeutics market size is expected to stand at $ 2.1 Mn in 2022 and is projected to reach $ 8.8 Mn by 2030, exhibiting a CAGR of 19% during the forecast period.
Get detailed information on our: Australia Primary Hyperoxaluria (PH) Therapeutics Market Report 2022 to 2030